Neurona Therapeutics Stock

www.neuronatherapeutics.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $481.17MM

Neurona Therapeutics is a company that strives to develop clinical-stage biotherapeutic treatments for neurological disorders with a focus on advancing regenerative cell therapy candidates. The company researches allogeneic therapies that come from stem cells harvested from donors. Neurona's proprietary therapy NRTX-1001 aims to reverse the effects of Alzheimer’s disease and other nervous system disorders. Neurona Therapeutics was founded by Arnold Kriegstein and Cory R. Nicholasin in 2008 and is headquartered in San Francisco, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Neurona Therapeutics, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Neurona Therapeutics Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Neurona Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
02/08/2024 Series E $120MM $xx.xx $399.51MM Alexandria Venture Investments, Berkeley Frontier Fund, Cormorant Asset Management, Euclidean Capital, Lyfe Capital, Schroders Capital, Sphera Biotech, Spur Capital Partners, Symbiosis, The Column Group, Ucb Ventures, Uc Investments, Viking Global Investors, Willett Advisors, Ysios Capital Partners
Price per Share
$xx.xx
Shares Outstanding
66,666,652
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Berkeley Frontier Fund, Cormorant Asset Management, Euclidean Capital, Lyfe Capital, Schroders Capital, Sphera Biotech, Spur Capital Partners, Symbiosis, The Column Group, Ucb Ventures, Uc Investments, Viking Global Investors, Willett Advisors, Ysios Capital Partners
03/19/2021 Series D $72.01MM $xx.xx $248.51MM Alexandria Venture Investments, Ironfire Ventures, Sphera Fund Management, The Column Group, Ucb Ventures
Price per Share
$xx.xx
Shares Outstanding
40,004,768
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Ironfire Ventures, Sphera Fund Management, The Column Group, Ucb Ventures
11/18/2019 Series C $15.03MM $xx.xx $154.19MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
8,350,160
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
02/08/2018 Series B $10.04MM $xx.xx $103.44MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
8,370,274
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
12/01/2015 Series A $23.5MM $xx.xx $78.33MM Alexsis De Raadt-St. James, The Column Group
Price per Share
$xx.xx
Shares Outstanding
26,111,111
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexsis De Raadt-St. James, The Column Group

Neurona Therapeutics Investors Also Invested in These Private Companies

Ironfire Ventures
UCB Ventures
California Institute for Regenerative Medicine
Topspin Consumer Partners
Sphera Funds Management
Harvard University Endowment
Berkeley Frontier Fund

Leadership & Board

Leadership

Cory Nicholas Ph.D
Co-Founder & Chief Executive Officer
Arturo Álvarez-Buylla Ph.D
Co-Founder & Scientific Advisor
John Rubenstein Ph.D
Co-Founder & Scientific Advisor
Arnold Kriegstein Ph.D
Co-Founder & Scientific Advisor
James Stutz
Chief Financial Officer & Chief Business Officer
Gautam Banik Ph.D
Chief Technology Officer
Catherine Priest Ph.D
Chief Development Officer
David Blum MD
Chief Medical Officer

Board

David Goeddel Ph.D
The Column Group
Erica Whittaker Ph.D
UCB Ventures
Raymond Kelleher Ph.D
Cormorant Asset Management
Robert Tjian Ph.D
The Column Group
Timothy Kutzkey Ph.D
The Column Group

Neurona Therapeutics stock FAQs

plusminus

Can you buy Neurona Therapeutics stock?

As Neurona Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Neurona Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Neurona Therapeutics stock?

To invest in a private company like Neurona Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Neurona Therapeutics stock?

Yes, you may sell the Neurona Therapeutics stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Neurona Therapeutics stock?

If you hold private company shares of Neurona Therapeutics – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Neurona Therapeutics on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Neurona Therapeutics a public company?

No, Neurona Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Neurona Therapeutics’ stock price?

Neurona Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Neurona Therapeutics private market stock price with Forge Data.
plusminus

What is Neurona Therapeutics’ stock ticker symbol?

Neurona Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Neurona Therapeutics News and Media Highlights

Neurona Raises $120M, Buoyed by Early-Stage Data for Epilepsy Cell Therapy

Neurona Therapeutics on Thursday announced that it has secured $120 million in funding, which will help it advance its pipeline of investigational off-the-shelf cell therapies. The California-based biotech will use the money to advance its lead candidate NRTX-1001, a regenerative neural cell therapy candidate being assessed in a Phase I/II trial for drug-resistant mesial temporal lobe epilepsy (MTLE), the most common form of focal epilepsy that can trigger ongoing seizures despite medical treatment.

Neurona Therapeutics Raises $120M in Funding

Neurona Therapeutics, a San Francisco, CA-based clinical-stage biotherapeutics company, raised $120M in funding
Browse Insights
Updated on: Dec 13, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.